Press release
Ischemic Stroke Clinical Trial Pipeline Advances as 50+ Companies Develop 55+ Pipeline Drugs Across Multiple Stages, Finds DelveInsight
Ischemic Stroke Pipeline Insights
Explore the latest breakthroughs in the Ischemic Stroke treatment landscape.
Learn more about the evolving Ischemic Stroke pipeline today @ https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Ischemic Stroke Pipeline Report
• In December 2025, Health Canada approved TNKase (tenecteplase) for acute ischemic stroke.
• In October 2025, Silver Creek Pharmaceuticals received FDA Fast Track designation for scp776 in acute ischemic stroke; Phase II ARPEGGIO trial completed enrollment, with topline results presented later that month.
• In July 2025, the FDA granted Fast Track designation to Revalesio's RNS60 for acute ischemic stroke, accelerating development based on Phase 2 data showing reduced brain tissue loss.
• The leading Ischemic Stroke companies include Athersys, Acticor Biotech, Avilex Pharma, AbbVie, Tasly Pharmaceutical, Revalesio Corporation, GNT Pharma, Biogen, DiaMedica Therapeutics, NuvOX Pharma, and others.
• Promising Ischemic Stroke therapies include MultiStem, Glenzocimab, Elezanumab, AVLX-144, and others.
Download for updates and the latest revolution in Ischemic Stroke care @ https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Ischemic Stroke Emerging Drugs Profile
• BMS-986177: Bristol-Myers Squibb/ Johnson & Johnson Innovative Medicine
Milvexian (BMS-986177) (Factor XIa) is an investigational anticoagulant compound. The drug is being developed by Bristol-Myers Squibb in collaboration with Johnson & Johnson. Currently the product is in Phase III stage of development for treatment of Ischemic Stroke.
• XY03 EA: Shijiazhuang Yiling Pharmaceutical Co. Ltd.
XY03 EA, is an investigational drug being developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd. XY03-EA decreased the cerebral injuries and NDS by increasing cerebral blood flow, improving brain energy metabolism, accelerating ROS clearance, suppressing inflammatory responses, and inhibiting autophagy in the MCAO/R model rats. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.
• NONO-42: NoNO Inc.
NoNO-42 is a nerinetide analog intended for use in people experiencing an acute ischemic stroke with or without thrombolytics. Compatibility of NoNO-42 with thrombolytics broadens the availability neuroprotection and neurorestoration to all hospital treated strokes. Currently, the drug is in Phase II stage of its development for the treatment of acute ischemic stroke.
For more information on the Ischemic Stroke Emerging Drugs Profile, download DelveInsight's comprehensive Ischemic Stroke Pipeline Insight report @ https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
The Ischemic Stroke Pipeline Report Provides
• Detailed insights about companies developing therapies for Ischemic Stroke, with aggregate therapies developed by each company.
• Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke treatment.
• Ischemic Stroke companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ischemic Stroke drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Ischemic Stroke market.
Learn more about Ischemic Stroke Drugs opportunities in our comprehensive Ischemic Stroke pipeline report @ https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Ischemic Stroke Companies
There are 50+ key companies, such as Athersys, Acticor Biotech, Avilex Pharma, AbbVie, Tasly Pharmaceutical, Revalesio Corporation, GNT Pharma, Biogen, DiaMedica Therapeutics, NuvOX Pharma, and others, developing therapies for Ischemic Stroke.
DelveInsight's Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Ischemic Stroke products have been categorized under various Molecule types such as:
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Discover the latest advancements in Ischemic Stroke treatment by visiting our website. Stay informed @ https://www.delveinsight.com/sample-request/ischemic-stroke-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr
Scope of the Ischemic Stroke Pipeline Report
• Coverage: Global
• Ischemic Stroke companies: Athersys, Acticor Biotech, Avilex Pharma, AbbVie, Tasly Pharmaceutical, Revalesio Corporation, GNT Pharma, Biogen, DiaMedica Therapeutics, NuvOX Pharma, and others.
• Ischemic Stroke Therapies: MultiStem, Glenzocimab, Elezanumab, AVLX-144, and others.
• Ischemic Stroke Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination.
• Ischemic Stroke Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
DelveInsight is a leading healthcare‐focused market research and consulting firm that provides clients with high‐quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe, helping them stay ahead of the growth curve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ischemic Stroke Clinical Trial Pipeline Advances as 50+ Companies Develop 55+ Pipeline Drugs Across Multiple Stages, Finds DelveInsight here
News-ID: 4394421 • Views: …
More Releases from DelveInsight
Epidermolysis Bullosa Clinical Trial Pipeline Robust as 20+ Companies Advance 21 …
DelveInsight's "Epidermolysis Bullosa - Pipeline Insight, 2026" report provides comprehensive insights about 20+ companies developing 21+ pipeline drugs in the Epidermolysis Bullosa pipeline landscape. It covers the Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Epidermolysis Bullosa treatment landscape.…
Traumatic Brain Injury Clinical Trial Pipeline Accelerates as 20+ Pharma Compani …
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Traumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Spinal Implants Market Size Report 2032: Market Porter's Five Forces Analysis, M …
DelveInsight's Spinal Implants Market Insights Report 2032 provides the current and forecast market analysis, individual leading Spinal Implants Companies market shares, challenges, Spinal Implants Market Drivers, barriers, trends, and key market Spinal Implants companies in the market.
To read more about the latest highlights related to the Spinal Implants Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/spinal-implants-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Spinal…
Genome Editing Market Size Report 2032: Market Porter's Five Forces Analysis, Ma …
DelveInsight's Genome Editing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Genome Editing Companies market shares, challenges, Genome Editing Market Drivers, barriers, trends, and key market Genome Editing companies in the market.
To read more about the latest highlights related to the Genome Editing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/genome-editing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Genome Editing Market…
More Releases for Ischemic
Acute Ischemic Stroke (AIS) Market Demand 2034
Market Overview
The Acute Ischemic Stroke (AIS) Market continues to expand due to rising global incidence of stroke, increasing aging populations, and rapid adoption of advanced diagnostic and therapeutic technologies. AIS occurs when a blood clot obstructs an artery supplying the brain, leading to reduced blood flow and neuronal damage. The disease represents the majority of all stroke cases worldwide, and healthcare systems are increasingly prioritizing early diagnosis and treatment to…
Rising Hypertension Fuels Growth In Acute Ischemic Stroke Therapeutics Market: K …
The Acute Ischemic Stroke Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Acute Ischemic Stroke Therapeutics Market Size During the Forecast Period?
The acute ischemic stroke therapeutics market has experienced significant growth in recent years. It is projected to rise from…
Ischemic Stroke Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Ischemic Stroke Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Ischemic Stroke Pipeline Report
• Over 50+ Ischemic Stroke…
Ischemic Cardiomyopathy Treatment Market Growth, Challenges, Opportunities and E …
"The new report has been added by qyresearch.com to provide detailed insight into the global Ischemic Cardiomyopathy Treatment market. The study will help to get a better understanding about the Ischemic Cardiomyopathy Treatment industry competitors, a channel for the distribution, Ischemic Cardiomyopathy Treatment growth potential, potentially disruptive trends, Ischemic Cardiomyopathy Treatment industry product innovations, market size value/volume (regional/country level, Ischemic Cardiomyopathy Treatment industry segments), market share of top players/products.
Due to…
Transient Ischemic Attack Market Forecast by 2025
Recent Transient Ischemic Attack market research and the current scenario as well as future market potential of "Global Transient Ischemic Attack Market Professional Survey Report 2020". The Transient Ischemic Attack Market comprehensively describes the market and prognosticates it to describe a highly illustrious growth during the anticipated years. The report offers an in-depth analysis of current and future Transient Ischemic Attack Market outlook across the globe. The report is projected…
Acute Ischemic Stroke Diagnosis And Treatment Market : Increased Usage of Advanc …
A recent report on global acute ischemic stroke diagnosis and treatment market has been analyzed by Transparency Market Research (TMR). The market for acute ischemic stroke diagnosis and treatment is expected to increase during the forecast period with the increasing incidence of strokes, technically advanced techniques, and successful results through treatment surgeries. Technological advancement and constant efforts made by leading companies are providing improved treatments for people suffering from ischemic…
